Conatus Pharmaceuticals Inc (CNAT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Conatus Pharmaceuticals Inc (CNAT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7972
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Conatus Pharmaceuticals Inc (Conatus) is a biotechnology company that develops and commercializes novel medicines for the treatment of liver diseases. The company’s lead pipeline candidate includes emricasan, an orally active pan-caspase protease inhibitor which is designed to reduce the activity of human caspases and is intended for the treatment of various indications such as post-orthotopic liver transplant, nonalcoholic steatohepatitis (NASH) cirrhosis and NASH fibrosis. Its other preclinical product candidates include IDN-7314, a pan-caspase inhibitor intended for the treatment of primary sclerosing cholangitis; and others. Conatus is headquartered in San Diego, California, the US.

Conatus Pharmaceuticals Inc (CNAT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
IDUN Pharma Raises USD1.1 Million in Financing 12
IDUN Pharma Raises Additional USD0.2 Million in Financing 13
Idun Pharma Raises USD0.23 Millin in Extended Venture Financing 14
Idun Pharma Raises US$0.3 Million In Venture Financing 15
Partnerships 16
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 16
Licensing Agreements 18
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 18
Conatus Pharma Enters into Sub-Licensing Agreement with Idun Pharma 19
Equity Offering 20
Conatus Pharma to Raise up to USD35 Million in Public Offering of Shares 20
Conatus Pharma Raises USD32.89 Million in Public Offering of Shares 21
Conatus Pharma Raises USD23 Million in Public Offering of Shares 23
Conatus Pharmaceuticals Completes IPO Of Shares For US$66 Million 25
Debt Offering 27
Conatus Pharmaceuticals Raises USD1 Million in Private Placement of Notes 27
Conatus Pharmaceuticals Inc – Key Competitors 28
Conatus Pharmaceuticals Inc – Key Employees 29
Conatus Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 01, 2018: Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates 31
May 02, 2018: Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates 33
Mar 07, 2018: Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates 34
Nov 01, 2017: Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates 36
Aug 02, 2017: Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates 38
May 04, 2017: Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates 40
Mar 15, 2017: Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates 41
Corporate Communications 43
Aug 31, 2017: Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer 43
Feb 07, 2017: Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member 44
Feb 02, 2017: Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management 45
Product Approvals 46
Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
IDUN Pharma Raises USD1.1 Million in Financing 12
IDUN Pharma Raises Additional USD0.2 Million in Financing 13
Idun Pharma Raises USD0.23 Millin in Extended Venture Financing 14
Idun Pharma Raises US$0.3 Million In Venture Financing 15
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 16
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 18
Conatus Pharma Enters into Sub-Licensing Agreement with Idun Pharma 19
Conatus Pharma to Raise up to USD35 Million in Public Offering of Shares 20
Conatus Pharma Raises USD32.89 Million in Public Offering of Shares 21
Conatus Pharma Raises USD23 Million in Public Offering of Shares 23
Conatus Pharmaceuticals Completes IPO Of Shares For US$66 Million 25
Conatus Pharmaceuticals Raises USD1 Million in Private Placement of Notes 27
Conatus Pharmaceuticals Inc, Key Competitors 28
Conatus Pharmaceuticals Inc, Key Employees 29
Conatus Pharmaceuticals Inc, Subsidiaries 30

List of Figures
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Conatus Pharmaceuticals Inc (CNAT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Generali France S.A.:企業の戦略・SWOT・財務分析
    Generali France S.A. - Strategy, SWOT and Corporate Finance Report Summary Generali France S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • FBN Bank (UK) Ltd:企業の戦略・SWOT・財務情報
    FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report Summary FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sulzer Ltd (SUN):電力:M&Aディール及び事業提携情報
    Summary Sulzer Ltd (Sulzer) is an industrial engineering company that manufactures and supplies pump equipment. It offers mixers, compressors, agitators and aeration equipment. The company provides repair and maintenance service solutions for turbines, pumps, compressors, motors, and generators. Sul …
  • Aker Solutions ASA:企業の戦略・SWOT・財務分析
    Aker Solutions ASA - Strategy, SWOT and Corporate Finance Report Summary Aker Solutions ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Exfo Inc.:企業の戦略・SWOT・財務分析
    Exfo Inc. - Strategy, SWOT and Corporate Finance Report Summary Exfo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Adept Technology, Inc.:企業の戦略的SWOT分析
    Adept Technology, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Nippon Shikizai Inc.:企業の戦略・SWOT・財務分析
    Nippon Shikizai Inc. - Strategy, SWOT and Corporate Finance Report Summary Nippon Shikizai Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • MDNA Life Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test is based on the science of mitochondrial DNA, a tissue-based prostate cancer diagnostics for prostate and other cancers. …
  • Lepu Medical Technology (Beijing) Co Ltd (300003):製薬・医療:M&Aディール及び事業提携情報
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical technology company that offers medical equipments, pharmaceutical products and healthcare services. The company’s products include cardiovascular interventional products, surgical cardiology products, peripheral interventio …
  • Alembic Pharmaceuticals Ltd (APLLTD):企業の財務・戦略的SWOT分析
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. APL also offers branded formulations in the areas of antibiotics and anti …
  • Scottish and Southern Energy plc:企業の戦略・SWOT・財務分析
    Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report Summary Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • Rose Petroleum plc (ROSE):石油・ガス:M&Aディール及び事業提携情報
    Summary Rose Petroleum plc (Rose Petroleum), formerly Vane Minerals plc is an oil and gas company. The company explores and produce oil and gas, silver, gold, copper, and uranium deposits across the US and Mexico. Its oil and gas project is located in Paradox Basin in Utah, the US, which covers over …
  • The Scotts Miracle-Gro Company (SMG):企業の財務・戦略的SWOT分析
    The Scotts Miracle-Gro Company (SMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Leaf Clean Energy Company (LEAF):企業の財務・戦略的SWOT分析
    Summary Leaf Clean Energy Company (Leaf Clean Energy) is a provider of renewable energy and sustainable technology investments. It offers growth and venture capital across the renewable energy industry to support novelty, well-managed and rapidly-growing companies. It operates and manages energy pro …
  • Dot Foods Inc:企業の戦略的SWOT分析
    Dot Foods Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • NCS Pte. Ltd.:企業の戦略・SWOT・財務情報
    NCS Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary NCS Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • JFE Holdings, Inc.:企業の戦略・SWOT・財務分析
    JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Talon Metals Corp.
    Talon Metals Corp. - Strategy, SWOT and Corporate Finance Report Summary Talon Metals Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • EnQuest PLC (ENQ):企業の財務・戦略的SWOT分析
    Summary EnQuest Plc (EnQuest) is an independent oil and gas exploration and production company. The company’s assets include producing oil fields, portfolio of discoveries, and new developments. Its oil and gas exploration assets are located in the UK North Sea and also have presence in oil basins o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆